09:42 AM EDT, 09/29/2025 (MT Newswires) -- AbbVie ( ABBV ) said Monday that it plans to sell its ovarian cancer drug Elahere in the UK at a list price equal to that in the US.

The pharmaceutical company said the treatment is aimed at patients who have received one to three prior systemic treatment regimens.

Price: 220.65, Change: +0.04, Percent Change: +0.02